Literature DB >> 21955142

Seizure outcomes following multilobar epilepsy surgery.

Rani A Sarkis1, Lara Jehi, Imad M Najm, Prakash Kotagal, William E Bingaman.   

Abstract

PURPOSE: Outcomes following unilobar surgeries for refractory epilepsy have been well described. However, little is known about long-term seizure outcomes following multilobar resections. The aim of the current study was to identify long-term seizure control and predictors of seizure recurrence in this patient population.
METHODS: Records of patients who underwent multilobar epilepsy surgery at the Cleveland Clinic between 1994 and 2010 were retrospectively reviewed. A postoperative follow-up of at least 6 months was required. Patients were classified as seizure free if they achieved an Engel class I at last follow-up. Long-term chances of seizure freedom were illustrated using a survival analysis, and predictors of recurrence were identified using Cox proportional hazard modeling. KEY
FINDINGS: Sixty-three patients with medically intractable epilepsy underwent multilobar surgical resections during the study period (mean follow-up of 4.6 years). Predominant resection types included extended occipital (temporoparietooccipital, parietooccipital, temporooccipital: 57%), frontotemporal (21%), and temporoparietal (17%). Mean age at surgery was 21.4 years and mean age at seizure onset was 10.1 years. Fifty-six percent of the patients underwent extraoperative invasive electroencephalography (EEG) evaluations. At 6 postoperative months, 71% (95% confidence interval (CI) 65-77) were seizure-free (SF), 64% (CI 58-70) were SF at 1 year, 52% (CI 46-59) were SF at 5 years, and 41% (CI 32-50) remained SF at 10 years. Forty-one patients had at least one breakthrough seizure after surgery (median timing of recurrence 6.1 months), with an Engel class 1 achieved again by last follow-up in 12 of these 41 cases. Nine patients required a reoperation. Patients who underwent extended occipital/posterior quadrant resections had more favorable outcomes as compared to the other groups. With multivariate analysis, the type of resection (p = 0.03), preoperative auras (p = 0.03), an incomplete resection (0.03), and the presence of postoperative spikes (p = 0.0003) correlated with seizure recurrence. The risk of seizure recurrence for an incomplete resection was 2.3 (CI 1.53-3.36), preoperative aura 2.3 (CI 1.34-3.87), and postoperative spikes on surface EEG 2.5 (CI 1.29-4.71). SIGNIFICANCE: A favorable outcome can be achieved in 41% of patients undergoing multilobar resections for epilepsy surgery at 10 years of follow-up. Close to one-third of patients who have breakthrough seizures after surgery are able to regain seizure freedom by last follow-up. Predictors of recurrence include resection type (frontotemporal and parietotemporal resections did worse), presence of preoperative aura, an incomplete surgical resection, and the presence of postoperative interictal discharges on EEG. Wiley Periodicals, Inc.
© 2011 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2011        PMID: 21955142     DOI: 10.1111/j.1528-1167.2011.03274.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

2.  Temporal Plus Epilepsy: Epileptic Territory Beyond the Temporal Lobes.

Authors:  Barbara C Jobst
Journal:  Epilepsy Curr       Date:  2016 Sep-Oct       Impact factor: 7.500

3.  [Surgery for posterior quadrant epilepsy].

Authors:  Shu-Li Liang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

Review 4.  Neurosurgical approaches to pediatric epilepsy: Indications, techniques, and outcomes of common surgical procedures.

Authors:  Jonathan Dallas; Dario J Englot; Robert P Naftel
Journal:  Seizure       Date:  2018-11-16       Impact factor: 3.184

Review 5.  Surgery for posterior quadrantic cortical dysplasia. A review.

Authors:  G Tamburrini; D Battaglia; E Albamonte; I Contaldo; L Massimi; M Caldarelli; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2014-10-09       Impact factor: 1.475

6.  Seizure Outcomes in Occipital Lobe and Posterior Quadrant Epilepsy Surgery: A Systematic Review and Meta-Analysis.

Authors:  Stephen C Harward; William C Chen; John D Rolston; Michael M Haglund; Dario J Englot
Journal:  Neurosurgery       Date:  2018-03-01       Impact factor: 4.654

7.  [Surgery for pediatric intractable epilepsy due to posterior quadrantic cortical dysplasia].

Authors:  Qing-Zhu Liu; Li-Xin Cai; Xiao-Yan Liu; Yu-Wu Jiang; Shuang Wang; Tao-Yun Ji; Wen Wang; Wei-Ke Cheng; Ruo-Fan Wang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

8.  The evolution of epilepsy surgery between 1991 and 2011 in nine major epilepsy centers across the United States, Germany, and Australia.

Authors:  Lara Jehi; Daniel Friedman; Chad Carlson; Gregory Cascino; Sandra Dewar; Christian Elger; Jerome Engel; Robert Knowlton; Ruben Kuzniecky; Anne McIntosh; Terence J O'Brien; Dennis Spencer; Michael R Sperling; Gregory Worrell; Bill Bingaman; Jorge Gonzalez-Martinez; Werner Doyle; Jacqueline French
Journal:  Epilepsia       Date:  2015-08-07       Impact factor: 5.864

9.  Long-term seizure outcome following resective surgery for epilepsy: to be or not to be completely cured?

Authors:  Takeharu Kunieda; Nobuhiro Mikuni; Sumiya Shibata; Rika Inano; Yukihiro Yamao; Takayuki Kikuchi; Riki Matsumoto; Jun Takahashi; Akio Ikeda; Hidenao Fukuyama; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-21       Impact factor: 1.742

10.  Which is the most appropriate disconnection surgery for refractory epilepsy in childhood?

Authors:  Haruhiko Kishima; Satoru Oshino; Naoki Tani; Yomoyuki Maruo; Shayne Morris; Hui Ming Khoo; Takufumi Yanagisawa; Kuriko Shimono; Takeshi Okinaga; Masayuki Hirata; Amami Kato; Toshiki Yoshimine
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-21       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.